See more : Cricut, Inc. (CRCT) Income Statement Analysis – Financial Results
Complete financial analysis of Vor Biopharma Inc. (VOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vor Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ATEME SA (ATEME.PA) Income Statement Analysis – Financial Results
- SML Isuzu Limited (SMLISUZU.BO) Income Statement Analysis – Financial Results
- Liberty Live Group (LLYVA) Income Statement Analysis – Financial Results
- Pinnacle Financial Partners, Inc. (PNFP) Income Statement Analysis – Financial Results
- Paramount Cosmetics (India) Limited (PARMCOS-B.BO) Income Statement Analysis – Financial Results
Vor Biopharma Inc. (VOR)
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| Gross Profit | -3.49M | -8.96M | -4.45M | -1.39M | -91.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 94.32M | 64.55M | 47.53M | 31.62M | 6.20M | 2.43M |
| General & Administrative | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Cost & Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Interest Income | 8.17M | 1.32M | 119.00K | 29.00K | 154.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 1.00M |
| Depreciation & Amortization | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| EBITDA | -114.37M | -90.89M | -67.58M | -41.95M | -10.17M | -2.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.04M | -93.42M | -69.02M | -43.37M | -10.42M | -2.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.17M | 1.32M | 119.00K | 29.00K | -422.00K | -1.29M |
| Income Before Tax | -117.86M | -92.09M | -68.90M | -43.34M | -10.84M | -4.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -119.00K | 427.70K | 608.00K | -289.00K |
| Net Income | -117.86M | -90.77M | -68.78M | -43.34M | -11.45M | -4.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| EPS Diluted | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| Weighted Avg Shares Out | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
| Weighted Avg Shares Out (Dil) | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to...
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research...
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the Compensation Committee of the Board of Directors granted stock options to...
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual...
Source: https://incomestatements.info
Category: Stock Reports